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Trends in vena caval interruption
Phillip S. Moore, MD,a Jeanette S. Andrews, MS,b Timothy E. Craven, MSPH,b Ross P. Davis, MD,a
Matthew A. Corriere, MD,a Christopher J. Godshall, MD,a Matthew S. Edwards, MD,a and
Kimberley J. Hansen, MD,a Winston-Salem, NC
Objective: This study examined the national use of vena cava filters (VCFs) from 1998 to 2005.
Methods: Methods for complex surveys were used to examine hospital discharge data from the Nationwide Inpatient
Sample (NIS) to determine the use of VCFs for the years 1998 to 2005. VCF placement in the absence of deep venous
thrombosis (DVT) or pulmonary embolus (PE) was categorized as prophylactic.
Results: During the study period, the estimated rate of hospitalizations per year with a diagnosis of DVT (odds ratio
[OR], 1.025; 95% confidence interval [CI], 1.019-1.032; P < .01) or PE (OR, 1.076; 95% CI, 1.069-1.083; P < .01)
rose significantly. The estimated weighted frequency of VCF placement increased from 52,860 procedures in 1998 to
104,114 procedures in 2005 (0.15% and 0.27% of all discharges, respectively), representing an 80% increase. VCF
placement significantly increased during hospitalizations with any diagnosis of DVT or PE, or both, and no DVT or PE
(P < .01 for each). Logistic regression models revealed that the rate of prophylactic VCF placement increased at a
significantly higher rate than VCF placement associated with DVT or PE (157% vs 42%; P< .01), after adjusting for age,
gender, and hospital characteristics. Prophylactic VCF placement in the setting of morbid obesity (P < .01) and head
injury (P  .03) rose significantly over time.
Conclusions: From 1998 to 2005, the estimated rates of prophylactic VCF placement increased at a significantly higher
rate than VCF placement in the setting of DVT or PE. Significant increases in the use of prophylactic VCFs were seen in
the setting of morbid obesity and head injury. (J Vasc Surg 2010;52:118-26.)Venous thromboembolism (VTE) is a major source of
morbidity and mortality in the United States (US). Ap-
proximately 100 persons per 100,000 will experience a first
occurrence of VTE each year, and 6% to 12% of these
patients will die within 1 month.1 The estimated incidence
of VTE has remained stable during the past 20 years, but
many asymptomatic episodes of VTE likely go undiag-
nosed.2,3 For patients with VTE, the treatment of choice is
anticoagulation.4 Interruption of the vena cava with a
variety of vena cava filters (VCFs) has also been adopted
when anticoagulation fails or is contraindicated.5-8
Established indications for the therapeutic placement
of a VCF are well recognized. In the setting of VTE, most
authorities agree that VCF placement is appropriate when
anticoagulation fails or is contraindicated. Free-floating
thrombus in the inferior vena cava and poor cardiopulmo-
nary reserve in the setting of VTE are a few examples of
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118relative indications for VCF placement that are also ac-
cepted by many vascular specialists.9 Today, VCFs are
being used for an expanding range of clinical indications,
including in patients without a diagnosis of DVT or VTE
but who are thought to be at high risk. Data to support the
use of these prophylactic VCFs are lacking.10
VCF use increased throughout the 1980s and
1990s.6,8,11 Since that time, additional devices, including
retrievable VCFs, have been introduced and many new
applications for VCFs have been reported. In light of these
apparent trends, the specific aims of this study were to (1)
describe the use of VCFs for established VTE and (2)
estimate the use and costs of prophylactic VCFs in the
absence of established DVT in the hospitalized US popu-
lation for a recent 8-year period using the Nationwide
Inpatient Sample (NIS).
METHODS
Data source. Data for the years 1998 to 2005 were
obtained from the NIS, part of the Healthcare Cost and
Utilization Project (HCUP), sponsored by the Agency for
Healthcare Research and Quality. The NIS is the largest
database of all-payer inpatient care in the US.12 It contains
data from approximately 1000 hospitals and 8 million
hospitalizations per year, approximating a 20% stratified
sample of inpatient admissions to US acute care hospitals.
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnosis and proce-
dure codes are the basis for reporting primary and second-
ary diagnoses and procedures. Patient demographics and
clinical outcomes are reported by the NIS. The data set
includes weights that can be used to produce national
estimates. Data are available to the public, and elements
that could identify individual patients are excluded by the
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tional Review Board for human subjects research.
Patient identification. Patients who underwent
placement of a VCF between 1998 and 2005 were identi-
fied using the ICD-9-CM procedure code 38.7 (interrup-
tion of the vena cava). Because surgical ligation and clip-
ping are procedures rarely used in contemporary practice,
interruption of the vena cava was assumed to be synony-
mous with VCF placement.6,13,14 Patients with a VCF and
a concomitant diagnosis of DVT or pulmonary embolus
(PE), or both, were identified using the ICD-9-CM codes
in Tables I and II, respectively. These patients were desig-
nated as having therapeutic VCF placement. Patients with-
out a concomitant ICD-9-CM code for DVT or PE were
designated as having prophylactic VCF placement. Patients
with a prophylactic VCF were then cross-referenced with a
list of individual ICD-9-CM codes and Clinical Classifica-
tions Software (CCS) categories for a number of diagnoses
or procedures that may account for VCF placement in the
absence of DVT or PE (Appendix, online only). Clinical
Classifications Software, developed by HCUP, assembles
similar ICD-9-CM codes into a smaller number of more
clinically meaningful categories for use with the NIS data-
base.
Statistical analysis. Trends in the use of VCFs, as well
as the diagnosis of DVT and PE, were examined using
estimated frequencies and percentages and logistic regres-
sion analyses. NIS stratum, clustering, and discharge-level
Table I. International Classification of Diseases, Ninth
Revision, Clinical Modification codes for identification of
patients with deep venous thrombosis
451 Phlebitis and thrombophlebitis
451.11 Femoral vein
451.19 Femoropopliteal, popliteal, tibial
451.2 Lower extremities, unspecified
451.81 Iliac vein
451.83 Deep veins, upper extremity
451.84 Unspecified veins, upper extremity
451.89 Axillary, jugular, subclavian
451.9 Unspecific site/not otherwise specified
453 Other venous embolism and thrombosis
453.2 Vena cava
453.3 Renal vein
453.40 Lower extremities, not otherwise specified
453.41 Lower extremities, proximal
453.42 Lower extremities, distal
453.8 Other specified veins
453.9 Other unspecified veins
671 Venous complications in pregnancy and the
puerperium
671.30 Deep vein thrombophlebitis, antepartum, unspecified
671.31 Deep vein thrombophlebitis, antepartum, delivered
671.33 Deep vein thrombophlebitis, antepartum condition or
complication
671.40 Deep vein thrombophlebitis, postpartum, unspecified
671.42 Deep vein thrombophlebitis, postpartum, delivered
671.44 Deep vein thrombophlebitis, postpartum condition or
complication
671.9 Phlebitis, thrombosis not otherwise specifiedweight information were used to produce national esti-mates accounting for stratified sampling methods accord-
ing to NIS recommendations. Logistic regression results
are presented as odds ratios (ORs) with 95% confidence
intervals (CIs) and as relative change in predicted probabil-
ities. Various subgroups were examined to determine
trends in VCF placement using linear regression weighted
by the inverse of the variance of the annual percentages.
Statistical significance was determined at P  .05. All
statistical analyses were conducted using SAS 9.1 software
(SAS Institute, Cary, NC).
RESULTS
From 1998 to 2005, a significant yearly increase was
documented in the prevalence of hospitalizations with a
diagnosis of DVT or PE, with an OR per year of 1.025 for
Table II. International Classification of Diseases, Ninth
Revision, Clinical Modification codes for identification of
patients with pulmonary embolism
415.1 Pulmonary embolism and infarction
415.11 Iatrogenic pulmonary embolism
415.12 Septic pulmonary embolism
415.19 Other pulmonary embolism
634.6 Spontaneous abortion complicated by
embolism
634.60 Complete
634.61 Incomplete
634.62 Unspecified
635.6 Legally induced abortion complicated by
embolism
635.60 Complete
635.61 Incomplete
635.62 Unspecified
636.6 Illegally induced abortion complicated by
embolism
636.60 Complete
636.61 Incomplete
636.62 Unspecified
637.6 Unspecified abortion complicated by embolism
637.60 Complete
637.61 Incomplete
637.62 Unspecified
638.6 Failed attempted abortion complicated by
embolism
639.6 Embolism not otherwise specified following
abortion
673.2 Obstetrical blood-clot embolism
673.20 Unspecified as to episode of care or not applicable
673.21 Delivered, with or without mention of antepartum
condition
673.22 Delivered, with mention of postpartum
complication
673.23 Antepartum condition or complication
673.24 Postpartum condition or complication
673.3 Obstetrical pyemic and septic embolism
673.30 Unspecified as to episode of care or not applicable
673.31 Delivered, with or without mention of antepartum
condition
673.32 Delivered, with mention of postpartum
complication
673.33 Antepartum condition or complication
673.34 Postpartum condition or complicationDVT (95% CI, 1.019-1.032; P  .01) and 1.076 for PE
1
1
2
2
2
2
2
2
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relative prevalence of hospitalizations with a diagnosis of
DVT or PE rose by 14% and 59%, respectively, while the
relative prevalence of hospitalizations with VCF placement
increased by 80% (Fig 1).
The estimated frequency of VCF placement increased
from 52,860 procedures in 1998 to 104,114 procedures in
2005, representing 0.15% and 0.27% of all hospitalizations,
respectively (Table III). Significant increasing trends in
VCF placement were observed during hospitalizations in
which there was any diagnosis of DVT or PE and no
diagnosis of DVT or PE (P  .01 for each; Fig 2). The
proportion of prophylactic VCFs increased from 16.9% in
1998 to 21.1% in 2005 (Fig 3). VCF placement was signif-
icantly more common in men (OR, 1.21; 95% CI, 1.19-
1.23; P .01) and in teaching institutions (OR, 1.54; 95%
CI, 1.45-1.63; P .01). VCF placement was significantly
less common in the West compared with the Midwest
(OR, 1.23; 95% CI, 1.10-1.38; P  .01), the North-
east (OR, 1.81; 95% CI, 1.63-2.00; P  .01), and the
South (OR, 1.48; 95% CI, 1.34-1.63; P  .01).
Multivariable logistic regression analysis adjusting for
Fig 1. Placement rates for vena cava filters (VCF) and d
embolism (PE) from 1998 to 2005.
Table III. National vena cava filter (VCF) placement by
year
Year
Weighted estimated
Hospitalizations with VCF, % VCFs placed, No.
998 0.15 52,860
999 0.15 54,756
000 0.15 56,380
001 0.17 63,676
002 0.21 78,443
003 0.22 83,657
004 0.24 92,743
005 0.27 104,114age, gender, region, teaching status of hospital, and Medi-care status, revealed that the relative rate of increase in
prophylactic VCF placement was significantly greater than
therapeutic VCF placement (P  .01), with relative in-
creases in predicted probability over the 8-year period of
157% for prophylactic VCF placement vs 42% for therapeu-
tic VCF placement (Fig 4 and 5).
Specific diagnoses or procedures associated with a high
risk of VTE (see Appendix, online only) were examined for
association with increased prophylactic VCF placement
(Table IV). Prophylactic VCFs were placed in combination
with major surgery or hemorrhage most commonly. Over-
all, 59% of patients with VCF placement had a separate
major surgery during the same hospitalization; however,
the rate of such placement was constant over the observa-
tion period.
Only prophylactic VCF placement in patients with a
diagnosis of morbid obesity or head injury changed signif-
icantly over time. In 1998, the estimated frequency of head
injury was 234,544, of which 0.55% received a prophylactic
VCF. In 2005, the estimated frequency of head injury rose
to 268,903, of which 1.34% received a prophylactic VCF
(P  .03). Similarly, the estimated frequency of morbid
obesity rose from 251,646 in 1998 to 728,104 in 2005.
The proportion of prophylactic VCF placement in these
patients increased significantly from 0.07% in 1998 to
0.20% in 2005 (P  .01). During the study period, pro-
phylactic VCF placement in the absence of all of the above
conditions or procedures was 10%, which was not a signif-
icant change.
DISCUSSION
Analysis of the NIS data showed that the use of VCFs
doubled between the years 1998 and 2005. Although the
prevalence of DVT and PE increased, so did therapeutic
VCF placement. The placement of prophylactic VCFs in-
creased by 157% during the study period, which was signif-
sis rates for deep vein thrombosis (DVT) and pulmonaryiagnoicantly more than therapeutic VCF placement. Significant
VT o
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were noted in patients with a diagnosis of morbid obesity or
head injury. Overall, approximately 20% of the VCFs placed
were prophylactic.
Reports in the 1980s and 1990s described increased
use of VCFs. Walsh et al11 reported that the placement of
VCFs in the US Medicare population increased signifi-
cantly during a 3-year period in the late 1980s. Likewise,
Stein et al6 examined the National Hospital Discharge
Survey and found that the estimated number of patients
who underwent VCF placement increased from 2000 in
1979 to 49,000 in 1999. Data from this report analyzing
the NIS showed that this trend continued during the next 6
years, in which100,000 VCFs were placed in 2005 alone.
Fig 2. Vena cava filter (VCF) placement rates in subgro
DVT, Deep vein thrombosis; PE, pulmonary embolism.
Fig 3. Percentage of patients with vena cava filters (VC
(PE), DVT or PE or both, and prophylactic VCF (no DConsidering all VCFs placed during this period, 21% ofthese VCFs were prophylactic. Recent single-institution
reports support these NIS data as well.7,8
Several different specialty groups have published rec-
ommendations for the use of VCFs in their particular
patient populations:
● The Society of American Gastrointestinal and Endo-
scopic Surgeons (SAGES) guidelines suggest the con-
sideration of a prophylactic VCF in morbidly obese
patients undergoing laparoscopic surgery who have
pre-existing venous stasis disease, a BMI 59 kg/m2,
truncal obesity, hypoventilation syndrome, or sleep
apnea.15
● The Eastern Association for the Surgery of Trauma
ith various degrees of venous thromboembolic disease.
ith deep vein thrombosis (DVT), pulmonary embolism
r PE).ups wFs) w(EAST) suggests the consideration of a prophylactic
es rep
ed lin
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bilized for a prolonged period of time and cannot
receive anticoagulation due to an increased risk of
bleeding.16
● In contrast, the American College of Chest Physicians
offers a recommendation against the use of VCFs as
primary prophylaxis for VTE in trauma patients. In-
stead, it supports the use of pneumatic compression
hose and duplex ultrasound screening in patients at
high risk for VTE who are unable to receive prophy-
laxis with low-molecular-weight heparin.17
With this lack of consensus, practice patterns are
likely to be highly variable across the nation and across
physicians.
There are a number of possible explanations for the
increased use of VCFs. These various specialty group rec-
ommendations may have the net effect of increased VCF
Fig 4. Adjusted probability of therapeutic vena cava filt
vein thrombosis or pulmonary embolism. The dotted lin
Fig 5. Adjusted probability of prophylactic vena cava fi
deep vein thrombosis or pulmonary embolism. The dottplacement. To date, no prospective randomized studieshave evaluated the use of prophylactic VCFs; consequently,
various specialty groups have created guidelines with only
retrospective data and expert opinion to guide them.
Moreover, VTE can affect any hospitalized patient and is
managed by a variety of physicians from different subspecial-
ties. A growing number of subspecialties are placing VCFs,
including vascular surgeons, general surgeons, trauma
surgeons, interventional radiologists, cardiologists, and
medical intensivists.18 Marmor et al19 showed that the rate
of VCF placement within a single institution varied greatly
depending on the specialty of the physician who was man-
aging the patient. Also, the bedside placement of VCFs is
making VCF available to critically ill patients who cannot
tolerate being moved to a fluoroscopic unit.20-22 Finally,
the increased use of prophylactic VCFs in morbidly obese
patients may reflect the 450% increase in the number of
bariatric procedures performed during a recent 4-year
cement in United States hospitalized patients with deep
resent 95% confidence intervals.
lacement in United States hospitalized patients without
es represent 95% confidence intervals.er plalter pperiod.23
t hype
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designed for subsequent removal.24 This retrievable VCF is
designed to protect the patient from PE during a finite
period of time and then be removed before it becomes
permanently incorporated into the vena cava. Before the
introduction of retrievable VCFs, a survey of trauma sur-
geons showed that substantially more surgeons would place
a prophylactic VCF if it were not permanent.16 In 2003,
the Food and Drug Administration approved the use of the
Gunther-Tulip (Cook, Bloomington, Ind) VCF as a re-
trievable device, and several different types of retrievable
VCFs are now available.25,26 Although physicians may be
more inclined to place a temporary VCF device, only a
fraction of retrievable VCFs are removed. Reported re-
trieval rates range from 2.4% to 44%.5,8,10,24,27-30
The finding that rates of DVT and PE in hospitalized
patients increased significantly from 1998 to 2005 was
unexpected (Fig 1). Prior studies have reported that the
incidence of VTE remained stable during the 1990s.2,3
This finding likely represents the acceptance and wide-
spread use of duplex ultrasound imaging and computed
tomography angiography to diagnoseDVT and PE, respec-
tively.31-34 These modalities are noninvasive, readily avail-
able, and carry less risk of complications than venography
and pulmonary angiography. As more patients are diag-
nosed with VTE, they are likely to be considered for VCF
placement.
The decision to place a VCFmust take into account the
accepted indications as well as short-term and long-term
effectiveness, risk, and cost. The effectiveness of a VCF to
prevent PE in the setting of DVT is widely accepted. Years
of experience with permanent VCFs has created a large
body of data on long-term safety. In the Prevention du
Risque d’Embolie Pulmonaire par Interruption Cave
(PREPIC) study, the only prospective randomized study of
VCF placement for the prevention of PE in patients with
DVT, patients with a VCF had a significantly lower rate of
Table IV. Specific diagnoses or procedures associated wit
hospitalizations with prophylactic vena cava filter (VCF) pl
Variable
Percentage of hosp
1998 1999
Major surgery during index hospitalization 65.5 60.7
Hemorrhage 28.8 30.8
Head injury 14.4 12.7
Stroke 7.2 6.2
Lower extremity/pelvis fracture 26.2 21.4
Malignancy 19.5 20.2
Solid/hollow organ injury 21.3 19.6
Spine injury/paralysis 12.5 11.7
Morbid obesity 1.9 2.4
None of the abovec 8.3 10.0
aCoding strategy for these diagnoses and procedures can be found in the A
bP value for trend from weighted regressions using annual estimated perce
cNone of the above includes no malignant hypertension (data for malignansymptomatic PE compared with patients treated with anti-coagulation alone at the 8-year follow-up. However, a
higher rate of recurrent DVT in patients with a VCF was
observed compared with those without a VCF. Despite
these findings, there was no difference in the rate of post-
thrombotic syndrome or death between the groups.35
Although rare, other serious complications of VCF
placement have been described, including caval perfora-
tion, caval occlusion, migration, and embolism leading to
cardiac tamponade.36-39 Complications increase the cost of
hospitalization, but the cost of VCF placement alone
should also be considered. Average cost of the device is
about $1100. In North Carolina, physician reimbursement
by Medicare for the placement of a VCF with a vena-
cavogram and use of fluoroscopy can range from $663 to
$1168. Reimbursement of the facility by Medicare for
inpatient VCF placement is difficult to accurately deter-
mine because the procedure is included in the Diagnosis
Related Group for that patient. However, total facility
reimbursement for outpatient placement of a VCF is
$2700. Applying this conservative estimate of outpatient
cost data ($663 physician  $2700 facility) to our NIS
estimates suggests that the placement of VCFs in 2005
consumed $330 million in health care expenditures.
Our study has several limitations. The NIS is a large
administrative database that is subject to inherent bias
related to coding inaccuracies.40 The official ICD-9-CM
procedure code for a VCF is termed, “interruption of the
vena cava.” Although we assumed that all of these proce-
dures reflected placement of a VCF, it is possible that a
small number reflect open ligation or clipping of the vena
cava. The strict definition of a therapeutic VCF includes not
only the diagnosis of DVT or PE, or both, but also a
contraindication to anticoagulation or failure of anticoag-
ulation. The NIS database does not include the specific
patient data necessary to make this determination. Conse-
quently, the search strategies used likely underestimate the
h risk of venous thromboembolism among
enta
ations with prophylactic VCF placement and specific
diagnosis or procedure by year
P valueb0 2001 2002 2003 2004 2005
.0 59.4 56.9 57.5 58.6 60.9 .50
.7 28.3 28.3 29.4 28.1 28.7 .15
.2 12.5 15.8 15.1 18.5 16.5 .03
.6 7.6 7.3 7.7 6.7 7.2 .67
.4 19.9 21.1 20.5 22.5 22.4 .72
.3 21.7 20.9 19.4 16.5 18.8 .08
.8 15.2 19.4 16.3 21.7 19.3 .52
.7 10.3 10.0 7.3 10.3 8.6 .15
.4 4.2 4.6 8.9 7.9 6.7 .01
.0 9.5 11.1 10.1 10.6 10.0 .24
ix, online only.
and standard errors (weight  1/SE2); significance at P .05.
rtension not shown).h hig
acem
italiz
200
57
30
14
7
20
22
14
9
2
11
ppend
ntagesnumber of prophylactic filters because a portion of patients
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for a VCF and were misclassified as “therapeutic.”
Moreover, VCFs placed in an outpatient setting, most
of which are prophylactic, are not captured by the NIS. In
our institution, 4 of the 182 (2%) VCFs placed during 2008
were performed in an outpatient setting. Consequently, the
NIS underestimated the total number of VCFs, and more
specifically the number of prophylactic VCFs, placed dur-
ing the study period. Despite these limitations, when search
criteria and statistical methods are applied similarly year to
year, trend data from the NIS should be valid. Finally, the
NIS does not provide information related to illness severity,
cause of death, or follow-up after hospitalization. There-
fore, this analysis does not provide meaningful outcome
data on the effect of VCFs on death.
CONCLUSIONS
From 1998 to 2005, the diagnosis of DVT and PE
increased significantly, the placement of VCFs increased
significantly, and the use of prophylactic VCFs grew the
fastest. A permanent VCF has been proven beneficial for a
strictly defined patient population with VTE and a contra-
indication to anticoagulation or failure of anticoagulation.
Little is known about the long-term efficacy and safety of
prophylactic VCFs and retrievable VCFs. Prospective ran-
domized trials of prophylactic VCFs within defined patient
populations are needed to maximize patient selection for
permanent and retrievable VCFs to minimize future com-
plications and costs associated with their use.
We would like to thank Leslie Hudson for her help with
ICD-9-CM coding.
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Dr Michael Stoner (Greenville, NC). Today, Dr Moore and
his colleagues examined the NIS [National Inpatient Sample] data
set to examine trends in vena caval filter placement. And what we
saw here was that a prophylactic filter seemed to outpace a thera-
peutic filter by the criteria established by the authors. There are a
variety of reasons for this that are speculated within themanuscript,
including divergent provider mix, mixed professional societal rec-
ommendations, and of course, financial and economic gain. In fact,
as one of my partners likes to point out, vena caval filter placement
is the best-paid 15 minutes in vascular surgery.
With that inmind, and within the context of cost-containment
and health care economics, I think that that makes this presenta-
tion very important. I have a few questions and comments for the
author. First of all, from the NIS data set, can we glean any efficacy
information regarding filter placement, especially in those patients
undergoing prophylactic filter placement? As you point out in the
manuscript and in the presentation, a great deal of money was
spent placing the filters, and my question is: Was this money well
spent?
Second, can you provide me any more insight about the
prophylactic filter group of patients? Specifically, I’d like to know if
there was an increase in the severity of medical illness or comor-
bidities over time that would account for this increased resource
utilization. If your logistic regression model corrected for this,
then this may simply be expanded indications.
And you raise the point that there is an increased incidence of
DVT [deep venous thrombosis] and PE [pulmonary embolism]
seen over time, and this may be part of increased imaging resource
utilization as well. We may simply be finding more occult venous
thrombotic pathology. Again, is there any indication in the NIS
data set that these were increased rates related to increasingly sicker
hospital population, or were these rates correlated with other
diagnoses or procedures? If not, then I would say that your
hypothesis in the manuscript is correct and that this is merely a
by-product of imaging over-utilization that is so common today.
And lastly, my question for you is sort of an open-ended one:
Where do we go from here? You point out that more and more
filters are being placed and that one of the principal driving forces
for this is the prophylactic indication. And this is often driven by
rather weak or soft indications. A randomized control trial to
better define these indications would be cumbersome and may notrequired. That leaves us essentially with societal recommendations
and even government and third-party payor payment restrictions.
I’d like to know what your thoughts are about this.
Dr Moore. In regards to your question about efficacy, the
NIS, unfortunately, does not allow us to answer a question like
that. You couldn’t tell from NIS data if a patient had a pulmonary
embolus before or after they had a filter placed, because it is just
discharge data and the timeline is not specified. So unfortunately,
that question really can’t be answered from the NIS.
As far as more insight into the prophylactic filter group, we
made an attempt to look at that group by cross-referencing them
with a large number of diagnoses and procedure codes that either
increase the risk of thromboembolic disease or make its prophylaxis
difficult. Interestingly, about 10% of prophylactic filters that were
placed were placed without any of those diagnoses or procedure
codes. And so then the question is, “Why was that filter placed?”
But again, the limitations of the NIS make it difficult to tell if this
is a sicker hospital population compared to one 10 years ago.
As far as cost-containment, I agree, a prospective multicenter
trial evaluating this would be very difficult. In order to have
enough events, PEs or PE-related deaths to determine if this is
helping people, you would need a large number of people. Unfor-
tunately, a large number of these prophylactic filters are placed in
trauma patients who are often difficult to follow-up. So I agree that
it would be a very difficult study to conduct, but we need to make
a strong effort at answering the question before somebody else
answers it for us for the purposes of cost-containment.
Dr VikramKashyap (Cleveland, Ohio). Beautiful snapshot of
what is happening with caval filters. My question is, can you tell us
howmany of these were removed? And perhaps the strategy would
be to find out which of these patients came back for secondary
hospitalization and had the code for removal of a foreign body.
DrMoore.One of the downsides to the NIS is that you can’t
track a patient over time. This could be one of the explanations for
why the DVT and PE diagnoses increased. If one patient gets
hospitalized 5 times during that year and has the diagnosis code of
DVT each time, it is going to get counted as five different DVTs.
For the same reason, it is impossible to track a patient to see if they
came back to get a filter removed.
Nevertheless, we did look at the removal code and it did not
change over time. Approximately 6000 foreign bodies were re-
moved each year during the study period, but it is a generic foreign
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Revision, Clinical Modification (ICD-9-CM), or Clinical C
patients with a prophylactic vena cava filter
Morbid obesity
ICD-9-CM 278.01
44.31
44.95
Head injury
CCS diagnosis 233
Stroke
CCS diagnosis 109
Spine injury/paralysis
CCS diagnosis 227
ICD-9-CM 343.2
344.00
344.01
344.02
344.03
344.04
344.09
344.1
344.89
344.9
438.53
Fracture of lower extremity/pelvis
CCS diagnosis 226
230
ICD-9-CM 808.0
808.1
808.2
808.3
808.41
808.42
808.43
808.49
808.51
808.52
808.53
808.59
808.8
808.9
Surgery of the eye, brain, spine, or other “major surgery”
CCS procedure 1, 2, 3, 5, 7, 9, 158
13-21
36
43, 44, 49
51, 52, 55, 56, 59, 60, 61
66
67
74, 75, 78, 79, 84
85, 86
89, 90, 92, 96, 99
104, 105, 106, 112, 114, 118
119, 120, 124, 129, 132, 134
144
145, 146, 147, 148, 152, 153, 154
157, 160, 161, 162, 164
167, 175
176
Hemorrhage/bleeding
CCS diagnosis 153
182
ICD-9-CM 246.3
252.8appropriate International Classification of Diseases, Ninth
lassifications Software (CCS) categories used to characterize
Morbid obesity
Gastric bypass
Laparoscopic gastric band
Intracranial injury
Acute cerebrovascular disease
Spinal cord injury
Congenital quadriplegia
Quadriplegia, unspecified
C1-C4, complete
C1-C4, incomplete
C5-C7, complete
C5-C7, incomplete
Other quadriplegia
Paraplegia, lower limbs
Other specified paralytic syndromes
Paralysis not otherwise specified
Other paralytic syndrome, bilateral
Fracture of neck of femur
Fracture of lower limb
Fracture of pelvis, acetabulum, closed
Fracture of pelvis, acetabulum, open
Fracture of pelvis, pubis, closed
Fracture of pelvis, pubis, open
Fracture of pelvis, ilium
Fracture of pelvis, ischium
Fracture of pelvis, multiple pelvic fractures with disruption
of pelvic circle
Fracture of pelvis, other
Fracture of pelvis, ilium, open
Fracture of pelvis, ischium, open
Fracture of pelvis, multiple pelvic fractures with disruption
of pelvic circle, open
Fracture of pelvis, other, open
Fracture of pelvis, unspecified, closed
Fracture of pelvis, unspecified, closed
Brain and spinal cord
Eye
Lung
Heart
Vascular
Spleen
Other procedures of the hemic/lymphatic system
Gastrointestinal/biliary
Hernias
Gastrointestinal
Genitourinary/transplant
Gynecologic
Otolaryngologic
Orthopedic
Orthopedic
Skin/breast
Transplant
Gastrointestinal bleeding
Hemorrhage during pregnancy
Thyroid hemorrhage
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280.0 Chronic blood loss anemia
285.1 Acute posthemorrhagic anemia
287.8 Other specified hemorrhagic conditions
287.9 Unspecified hemorrhagic conditions
363.61 Choroidal hemorrhage, unspecified
363.62 Expulsive choroidal hemorrhage
374.81 Hemorrhage of the eyelid
376.32 Orbital hemorrhage
377.42 Hemorrhage into optic nerve sheath
379.23 Vitreous hemorrhage
459.0 Hemorrhage, unspecified
530.21 Ulcer of esophagus with bleeding
535.01 Acute gastritis, with hemorrhage
535.11 Atrophic gastritis, with hemorrhage
535.21 Gastric mucosal hypertrophy, with hemorrhage
535.31 Alcoholic gastritis, with hemorrhage
535.41 Other specified gastritis, with hemorrhage
535.51 Unspecified gastritis and gastroduodenitis, with
hemorrhage
535.61 Duodenitis, with hemorrhage
535.71 Eosinophilic gastritis, with hemorrhage
568.81 Hemoperitoneum
569.85 Angiodysplasias of intestines with hemorrhage
602 Prostate hemorrhage
626.2 Excessive menstruation
634.10-634.12 Spontaneous abortion with hemorrhage
635.10-635.12 Legal abortion with hemorrhage
636.10-636.12 Illegal abortion with hemorrhage
637.10-637.12 Induced abortion with hemorrhage
638.1 Attempted abortion with hemorrhage
639.1 Postabortion hemorrhage
664.54 Perineal hematoma, postpartum
665.70-665.72, 665.74 Vaginal hematoma
666.00, 666.02, 666.04 Postpartum hemorrhage, third stage
666.10, 666.12, 666.14 Other immediate postpartum hemorrhage
666.20, 666.22, 666.24 Delayed and secondary postpartum hemorrhage
674.30, 674.32, 674.34 Other complications of obstetrical surgical wounds
772.5 Adrenal hemorrhage
784.7 Epistaxis
784.8 Hemorrhage of the throat
786.3 Hemoptysis
958.2 Secondary or recurrent hemorrhage (trauma)
998.11, 998.12 Hemorrhage complicating a procedure
Hollow/solid organ injury or vascular injury
CCS diagnosis 234 Crushing injury or internal injury
Malignancy
CCS diagnosis 11 Cancer of head and neck
12 Cancer of esophagus
13 Cancer of stomach
14 Cancer of colon
15 Cancer of rectum and anus
16 Cancer of liver and intrahepatic bile duct
17 Cancer of pancreas
18 Cancer of other GI organs; peritoneum
19 Cancer of bronchus; lung
20 Cancer; other respiratory and intrathoracic
21 Cancer of bone and connective tissue
22 Melanomas of skin
23 Other nonepithelial cancer of skin
24 Cancer of breast
25 Cancer of uterus
26 Cancer of cervix
27 Cancer of ovary
28 Cancer of other female genital organs
29 Cancer of prostate
30 Cancer of testis
31 Cancer of other male genital organs
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32 Cancer of bladder
33 Cancer of kidney and renal pelvis
34 Cancer of other urinary organs
35 Cancer of brain and nervous system
36 Cancer of thyroid
37 Hodgkin’s disease
38 Non-Hodgkin’s lymphoma
39 Leukemias
40 Multiple myeloma
41 Cancer; other and unspecified primary
42 Secondary malignancies
43 Malignant neoplasm without specification of site
44 Neoplasms of unspecified nature or uncertain behavior
